Island Pharmaceuticals Limited is a drug research and repurposing company focused on developing preventative and therapeutic drugs for viral infections. The company concentrates on areas of unmet medical need for antiviral therapeutics to address urgent viral diseases, public health threats, and biosecurity concerns. Island Pharmaceuticals executes a dual development strategy centered on its lead product candidates, ISLA-101 and Galidesivir. ISLA-101 is designed for the prevention and treatment of dengue fever and other mosquito-borne diseases, with ongoing collaboration agreements with Monash University and the National Cancer Institute. The company also maintains a cooperative research and development agreement with the U.S. Army in preparation for Phase 2a/b clinical studies. Operating across Australia and the United States, Island Pharmaceuticals operates within the healthcare and biotechnology sector, addressing critical gaps in infectious disease treatment and prevention.